038. Roflumilast, a PDE-4 inhibitor induces phagocytic activity in Greek chronic obstructive pulmonary disease (COPD) patients

Résumé fourni par la source

OBJECTIVE: Chronic obstructive pulmonary disease (COPD) appears with progressive airflow obstruction and abnormal inflammatory response which is still untreatable. A new approach concerning COPD treatment includes controlling the inflammation for its important role in the exacerbation. Recently, roflumilast (DAXAS) has been added as a therapeutic option for COPD. DAXAS which was accepted by Food and Drug Administration (FDA), included in treatment of severe COPD in “The Global Initiative for GOLD” guideline, is an oral phosphodiesterase-4(PDE-4) inhibitor that targets inflammatory cells involved in triggering COPD exacerbations. The objective of the current study was to evaluate a PDE4 (DAXAS) inhibitor for its contribution to phagocytic activity in COPD patients. METHODS: Twenty-one patients diagnosed with COPD received DAXAS once daily for six months and more in combination with other COPD treatments (including long-acting muscarinic antagonists (LAMA), and long-acting β2-agonist/inhaled corticosteroids -LABA/ICS). Peripheral blood samples were taken from the COPD patients at indicated time-points. The first sample was taken before receiving roflumilast, the second after three months and the third after six months. Examination of defective phagocytosis by flow cytometry was made by the FagoFlowEx(®) Kit (Exbio, Diagnostics). Statistical analysis was performed by Statistica software. Furthermore, FEV(1) and FVC spirometry values were measured. RESULTS: Statistical analysis showed that Stimulation index of phagocytic activity at 3 and 6 months is statistical significantly different compared to the first sample before receiving roflumilast (P<0.001). Similarly, FVC values showed statistically significant differences between 3 and 6 months values when compared to the first sample (0.007). Numerical differences were found between the indicated time-points concerning the FEV(1) values at the edge of significant difference (0.08). CONCLUSIONS: Treatment with roflumilast induces phagocytic activity which improves lung function and is estimated to reduce exacerbations.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.